Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Bezlotoxumab was associated with a substantially lower rate of recurrent <em>C. difficile</em> infection compared to placebo with a good safety profile.</p>

Approved Drug Demonstrates Efficacy in Battling Potent Bacterial Infection